Vaccine plus β-glucan and GM-CSF for high-risk neuroblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a vaccine, combined with two other immune-boosting drugs (β-glucan and GM-CSF), to see if it can help keep neuroblastoma from coming back. It's for people who have already completed standard treatment and are in remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with high-risk neuroblastoma.
- You have completed initial treatment and are in remission (complete response).
- Your kidney, liver, and blood counts meet certain minimum levels.
- You have not had a stem cell transplant within the last 2 weeks before starting the vaccine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a vaccine combined with a substance called beta-glucan to help the immune system recognize and fight neuroblastoma cells. It is for children who have already completed treatment for high-risk neuroblastoma and are now in remission.
This study tests a new combination of drugs (a GSL synthetase inhibitor, GM-CSF, and possibly an immune checkpoint inhibitor) for people with high-risk neuroblastoma that has already been treated. It aims to see if this combination can help shrink tumors or slow the disease.
This trial tests a combination of naxitamab, GM-CSF, and isotretinoin as maintenance therapy for children with high-risk neuroblastoma who have achieved their first complete response after initial treatment. The goal is to help keep the cancer from coming back.
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.